Closed consultations

38 results

  • Public consultation on applications to be considered by the MSAC (July 2022)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 28-29 July 2022. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. Consultation input must be received by no later than Friday, 10 June 2022 for it to be considered by... More
    Closed 10 June 2022
  • Review of discount rate in the PBAC guidelines - Phase 2 consultation

    The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment (HTA) and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry. As agreed under Clause 5.2 of the Agreement, advice was sought from the Pharmaceutical Benefits Advisory Committee (PBAC) on whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best... More
    Closed 1 June 2022
  • Public consultation on items to be considered by the PBAC (July 2022)

    Consultation is now open for items listed on the July 2022 PBAC agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Input can be submitted via the online survey. A copy of the questions asked in the survey can... More
    Closed 25 May 2022
  • Review of discount rate in the PBAC guidelines - Phase 1 consultation

    The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment (HTA) and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry. As agreed under Clause 5.2 of the Agreement, the Minister for Health has sought the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) on whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best... More
    Closed 29 April 2022
  • Public consultation on items to be considered by the PBAC (May 2022 Intracycle Meeting)

    PBAC Intracycle meetings are held between the main PBAC meetings. Submission items considered by the PBAC at these meetings typically relate to matters arising from previous submissions but can also relate to new medicines. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. All public consultation inputs are considered by the PBAC when... More
    Closed 8 April 2022
  • Public consultation on applications to be considered by the MSAC PASC (April 2022)

    Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 13-14 April 2022. PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications... More
    Closed 11 March 2022
  • Public consultation on applications to be considered by the MSAC (March/April 2022)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 31 March - 1 April 2022. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. It is anticipated that the below-mentioned applications will proceed to MSAC in March/April... More
    Closed 11 February 2022
  • Public consultation on items to be considered by the PBAC (March 2022)

    Consultation is now open for items listed on the March 2022 PBAC agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Input can be submitted via the online survey which includes an option to upload a file. You... More
    Closed 27 January 2022
38 results. Page 2 of 2